Screen%20Shot%202018-11-01%20at%2010.14.03%20AM_0.png

Practical management of rheumatic immune-related adverse events with immune checkpoint inhibitors

Jack Cush, MD
Joint Bone Spine has published a full read review of the management of immune-related adverse events (irAEs) in patients receiving Immune checkpoint inhibitors (ICIs) for cancer.
RheumNow Podcast square

NHANES, Numbers, & Risk (7.18.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com along with interesting case questions from "Ask Cush Anything".

human figures on blue circle

1 in 5 Patients are Unaware of their Arthritis Diagnosis

Jack Cush, MD

Current CDC numbers suggest that arthritis (any type) affects an estimated 67.1 million (27.9% ) adults in the USA.  Interestingly, 1 in 5 do not know their arthritis subtype (21.6%, 14.4 million).

Puzzle pieces

ICYMI: Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

Mrinalini Dey, MD

This article was originally published June 12, 2025, and is being shared again this week as part of our In Case You Missed It series. Enjoy! 

Puzzle pieces

Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

Mrinalini Dey, MD

Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment.

RheumNow Podcast square

MTX Fails Knee OA (6.6.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

RheumNow Podcast square

Diagnosing Neuropsychiatric SLE (5.23.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com - including views on the vagus nerve, NPSLE and CAR-T mania.

ra.hands2_.JPG

Hydroxychloroquine for Everyone

Jack Cush, MD

Nearly 25 years ago, while lecturing on best therapies for rheumatoid arthritis (RA), I loudly stated that hydroxychloroquine was “useless” and, deservedly, I was “boo-ed” off stage.

RheumNow Podcast square

Vitamin D Headlines (5.9.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and lupus highlights from the past week on RheumNow.com. Triple positivity, the gut and CRPS, and hope for better outcomes with Vitamin D therapy. 

VitD_1.jpg

D-Lay Trial: High-Dose Vitamin D Retards Multiple Sclerosis

Jack Cush, MD

A randomized clinical trial with oral high-dose cholecalciferol ( vitamin D3) was shown to prevent or delay the onset of clinically isolated syndrome (CIS), typical for multiple sclerosis (MS).

RheumNow Podcast square

Keys to Mastery (5.2.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, articles and drug approvals from the past week on RheumNow.com. This podcast marks the beginning of our Lupus Campaign called "Lupus Unlocked: Keys to Mastery". This month's campaign on Lupus is sponsored by Aurinia.

pregnancy.sperm_.jpg

EULAR Guidelines on Reproductive Health

MedPage Today
  • Many rheumatologic conditions such as rheumatoid arthritis and lupus often strike women during their reproductive years, with drugs being the primary therapies.
  • Experts assembled by EULAR determined that most of the common medi

Social

Rheums! Question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. https://t.co/HsqM9xLNtP https://t.co/voONsOLeSK

Links:

Dr. John Cush @RheumNow ( View Tweet )
2 weeks ago
Lichenoid rash vs SCLE? JAMA Dermatology case - 60yoM w/ https://t.co/xl11CwB1AJ problems & meds has pink-red papules (central hypopigmentation) on arms, chest, back (no fungus). Bx= lichenoid dermatitis. Rash worsened, red & annular; Dx now SCLE +ANA/Ro/La) from diltiazem. SCLE

Links:

Dr. John Cush @RheumNow ( View Tweet )

1 month ago
Predictors and Outcomes in Systemic Sclerosis The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will https://t.co/C4Pro6b0Jw
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
EULAR 2025 – Day 2 Report Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options https://t.co/rys0pA6D6j
Dr. John Cush @RheumNow ( View Tweet )
1 month 1 week ago
Which CAR-based strategies would you consider to treat severe refractory #SLE based on data presented at #EULAR2025? @RheumNow

Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )

1 month 1 week ago
from Rituximab to BiTES to CAR T, always looking for deeper B cell depletion Safety data from CC312 CD19/CD3/CD28, a triple engager in refractory moderate-to-severe SLE So far so good but how far do we need to go? #EULAR2025 @RheumNow LB0007

Aurelie Najm @AurelieRheumo ( View Tweet )

1 month 1 week ago
🌳#WILLOW: TLR7/8 inhibition with enpatoran led to greater BICLA response, IFN signature reduction & skin improvement (CLASI-50/70) in active SLE vs placebo at 24wks. Most benefit seen in pts with high IFN-GS or GC use. Good tolerability. @RheumNow #EULAR2025 #LB0004

Mrinalini Dey @DrMiniDey ( View Tweet )

1 month 1 week ago
#EULAR2025 Abstr#POS0321 In addition to complete renal response attainment as you already know, exploratory analysis from REGENCY showed Obinutuzumab+SOC reduced #lupus nephritis flare and unfavourable kidney outcomes vs PBO+SOC. Longterm kidney survival protection @RheumNow https://t.co/vRFb94TXaQ

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 month 1 week ago
#EULAR2025 Abstr#OP0074 Manufacturing time for CAR-T can be a hindrance. Preliminary study (N=10 #SLE patients) of CD19/BCMA dual-targeting CAR-T developed on the novel FasTCAR-T platform with next-day manufacturing, showed promising efficacy and safety signals @RheumNow https://t.co/bgF04qe9C7

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 month 2 weeks ago
#EULAR2025 Abstr#OP0032 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 5 #SLE patients in Phase 1. Advantages over autologous/allogenic: -No apheresis -No conditioning chemo -Shorter hospital stays ~3days -Ability to redose in partial responder @RheumNow https://t.co/qimC94pVU1

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 month 2 weeks ago
×